Última actualización 15 de junio de 2026
Key finding
HbA1c decreased from 7.39% to 7.10% (p=0.045)
Switching from premixed insulin to the insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) improved glycemic control in participants with type 2 diabetes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
Switching from premixed insulin to the insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) improved glycemic control in participants with type 2 diabetes.
These findings are clinically significant as they suggest that iGlarLixi may offer a more effective and manageable treatment option for individuals with type 2 diabetes, potentially leading to better long-term health outcomes. The reduction in insulin dosage and weight loss are particularly important for improving patient adherence and reducing the risk of diabetes-related complications.
Single-arm study design limits comparison with a control group. Results may not be generalizable to all populations with type 2 diabetes. Lack of long-term follow-up data to assess sustained effects.
Published in
Publication details and source links for this paper.
Nika AKT, Andrijana K, Mitja K. Switching from Premixed Insulin to iDegLira Improves Glycemic Control in Type 2 Diabetes. Frontiers in Endocrinology. 2025;16:1715800. doi:10.3389/fendo.2025.1715800
HbA1c decreased from 7.39% to 7.10% (p=0.045)
Average fasting glucose decreased from 8.25 mmol/L to 6.92 mmol/L (p<0.031)
Total daily insulin dose decreased from 44.5 units/day to 23.1 units/day (p<0.001)
Body weight decreased from 86.5 kg to 84.5 kg (p<0.001)
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Body weight, Diabetes-related misconceptions, Fasting blood sugar (FBS), and 3 more.
This study contributes evidence to
Primary intervention
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
4
Related topics
6
Evidence pairs
750
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Relación de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Body weight
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Body weight
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Diabetes-related misconceptions
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Diabetes-related misconceptions
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Fasting blood sugar (FBS)
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Fasting blood sugar (FBS)
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time in range
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Time in range
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Total daily insulin dose
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Insulin Resistance.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
All studies measuring Body Weight
Measures Body Weight as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
2 results
3 results
3 results
2 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies may improve CGM Time in Range.
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with generally consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 9 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Insulin Resistance.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Total daily insulin dose
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies appears to improve Fasting Glucose.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Fasting blood sugar (FBS)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
